(CercleFinance.com) – UBS reaffirms its ‘buy’ recommendation on Ipsen as well as its price target of 145 euros, a target which contains 25% potential growth for the title of the French pharmaceutical laboratory, pending its publication for the second trimester.
‘We are awaiting comments on the preparation for the launch of elafibranor and its likely trajectory, as well as on the erosion of somatuline given the recent approval of generics,’ indicates the broker in the summary of its note.
Copyright © 2024 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. Cercle Finance cannot be held responsible directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional advisor before making any investment. This indicative information does not in any way constitute an inducement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends using the buttons below.
